Core Insights - PetVivo Animal Health, Inc. has received formal acknowledgment from Health Canada for its product Spryng® with OsteoCushion® Technology as a veterinary medical device, marking a significant milestone in the company's global commercialization strategy [1][2][3] Company Overview - PetVivo Holdings, Inc. operates as an emerging biomedical device company focused on innovative medical technologies for companion animals and equine athletes, leveraging human therapies for animal treatment in a capital-efficient manner [6][7] - The company has a robust pipeline of products, including Spryng® and PrecisePRP®, protected by twelve patents and six trade secrets [7] Product Details - Spryng is an intra-articular injectable device designed to support joint health and manage lameness and other joint-related issues in animals [2][4] - The product is currently available in the United States and through select international distribution partners, with plans for commercial availability in Canada anticipated in the second quarter of 2026 [4][3] Regulatory Milestone - The acknowledgment from Health Canada serves as an important endorsement of the company's scientific and regulatory strategy, reflecting its commitment to providing innovative solutions for animal health [3][4] - Despite the regulatory acknowledgment, Spryng is not expected to be immediately available in Canada due to ongoing infrastructure development and operational requirements [3]

Core Insights - PetVivo Holdings, Inc. has appointed Josh Ruben to its Board of Directors, enhancing its leadership team with expertise in healthcare finance and corporate strategy [1][2][4] - Ruben's background includes significant experience in executing multi-billion-dollar mergers and acquisitions, which will support PetVivo's growth and market expansion efforts [2][4] - The company focuses on innovative medical therapeutics for companion animals, particularly in treating osteoarthritis and joint conditions [2][6] Company Overview - PetVivo Holdings, Inc. operates in the biomedical device sector, specifically targeting the commercialization of medical devices and therapeutics for companion animals [6] - The company aims to leverage human therapies for animal treatment, allowing for a quicker market entry compared to traditional pharmaceuticals [6] - PetVivo has a diverse product pipeline, including its lead product SPRYNG, which utilizes OsteoCushion technology for joint-related afflictions in animals [7] Leadership and Strategy - Josh Ruben, as the Managing Director of Life Sciences at Trinity Capital, brings a wealth of experience in venture lending and investment banking, particularly in life sciences [4][5] - His expertise will be instrumental in guiding PetVivo's capital strategy and maximizing value creation across veterinary and emerging human applications [5] - The company holds a portfolio of twelve patents and six trade secrets, protecting its innovative biomaterials and production processes [7]